TAK-761-4009
Completed
A Study of ADVATE in People With Hemophilia A in India
Clinicaltrials.gov
#NCT04985682EudraCT
#2022-004149-11About this clinical trial
The main aim of this study is to learn more about side effects of Advate when given as standard treatment to people with hemophilia A who have already been treated. The study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study. Participants will need to visit the study doctor 5 times in total during the study. During these visits, study data will be collected by the study doctor.
IN
Interventional Phase 4 clinical trial.
At a glance
What medical conditions were being studied?
Hemophilia A
What was the clinical trial testing?
ADVATE
How many participants were enrolled?
50
Were placebos part of the clinical trial?
No
When was the clinical trial conducted?
Jan 2022 - Feb 2023
How long was participation in the clinical trial?
Participants will take part in this study for about 7 to 8 months, with 6 months of treatment.
Key requirements
Sex
All
Age
All
Healthy volunteers?
No
Entry criteria
People of all ages can take part in this study.
Must have been diagnosed with congenital hemophilia A.
Cannot have been treated for their condition with non-Factor VIII products in the last 6 months.
Additional entry criteria will be discussed with the study doctor.